New cancer clinical trial: Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer

Published on: August 29, 2018 at 12:00PM
Condition:   Advanced Metastatic Cancer
Interventions:   Biological: Nivolumab;   Biological: Ipilimumab
Sponsors:   Parker Institute for Cancer Immunotherapy;   Bristol-Myers Squibb;   Cancer Research Institute, New York City
Not yet recruiting
https://ift.tt/2Pl5OlI